05373cam a2200565Ma 4500001001300000003000600013005001700019006001900036007001500055008004100070040013800111015001900249016001800268020001800286020001500304020001800319020001500337035002100352050001300373082001500386100002500401245012000426250001200546260004200558300003400600336002600634337002600660338003600686588002600722500002000748520047700768505057801245505059101823505057902414505060002993505058503593650002604178650001904204650003004223650005204253650004504305650005604350650004604406650003204452650004604484655002204530700004504552776013504597856007504732ocn911246573OCoLC20190328114811.0m     o  d        cr cnu---unuuu150620s2015    ne      o     001 0 eng d  aEBLCPbengepncEBLCPdOPELSdE7BdUIUdUV0dOCLCFdOCLCQdBUFdOCLCOdMERERdOCLCOdOCLCQdU3WdOCLCOdD6HdUKMGBdWYUdOCLCOdOCLCA  aGBB6G63162bnb7 a0180868982Uk  z9780444626493  z0444626492  z9780444626677  z0444626670  a(OCoLC)911246573 4aRC271.C504a616.9940611 aAvenda�no, Carmen.10aMedicinal chemistry of anticancer drugs / h[electronic resource]cby Carmen Avenda�no and J. Carlos Men�endez.  a2nd ed.  aAmsterdam :bElsevier Science,c2015.  a1 online resource (767 pages)  atextbtxt2rdacontent  acomputerbc2rdamedia  aonline resourcebcr2rdacarrier0 aPrint version record.  aIncludes index.  aMedicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents. Antitumor chemotherapy is a very active field of research, and a huge amount of information on the topic is generated every year.0 aFront Cover; Medicinal Chemistry of Anticancer Drugs; Copyright; Contents; Foreword; Preface; Abbreviations; Chapter 1: General Aspects of Cancer Chemotherapy; 1. Introduction: Some General Comments About Cancer; 2. Tumorigenesis and Oncogenes: Pharmacogenomics; 3. Early Diagnosis of Cancer and Its Therapeutic Relevance; 4. A Brief History of Cancer Chemotherapy; 5. General Comments About Anticancer Drug Discovery; 6. Combination Therapy and Personalized Anticancer Treatments; 7. Natural Products in Cancer Chemotherapy; 8. A Brief Comment About Cancer Nanotechnology.8 a9. Summary of FDA-Approved Anticancer DrugsReferences; Chapter 2: Antimetabolites That Interfere with Nucleic Acid Biosynthesis; 1. Introduction; 2. Inhibitors of the Biosynthesis of Uridylic Acid; 3. Inhibitors of Ribonucleotide Reductase; 3.1. Structure and Catalytic Cycle of Ribonucleotide Reductase; 3.2. Gallium Salts and Complexes; 3.3. Radical Scavengers; 3.4. Substrate Analogs as Ribonucleotide Reductase Inhibitors; 3.5. Allosteric Inhibition of Ribonucleotide Reductase via Inhibition of Purine Nucleoside Phosphorylase; 4. Inhibitors of the Biosynthesis of Thymidilic Acid.8 a4.1. Thymidylate Synthase4.2. 5-Fluorouracil and Floxuridine; 4.3. 5-Fluorouracil Prodrugs; 4.4. Modulation of 5-Fluorouracil Activity; 4.4.1. Decreased Degradation of 5-FU; 4.4.2. Enhancement of the Inhibition of Thymidylate Synthase by 5-FU; 4.4.3. Enhancement of 5-FU Activation; 4.5. Trifluridine; 4.6. Folate-Based Thymidylate Synthase Inhibitors; 5. Inhibitors of Dihydrofolate Reductase; 5.1. Classical DHFR Inhibitors; 5.2. Nonclassical (Lipophilic) DHFR Inhibitors; 6. Inhibitors of the De Novo Purine Biosynthesis Pathway; 6.1. Inhibitors of PRPP Amidotransferase.8 a6.2. Inhibitors of Glycinamide Ribonucleotide Formyltransferase6.3. Inhibitors of Phosphoribosylformylglycinamidine Synthetase; 6.4. Inhibitors of 5-Aminoimidazole-4-Carboxamide Ribonucleotide Formyltransferase; 6.5. Thiopurines and Related Compounds; 7. Inhibitors of Adenosine Deaminase; 8. Inhibitors of Late Stages in DNA Synthesis; 8.1. Pyrimidine Nucleosides; 8.2. Purine Nucleosides; 9. Antimetabolite Enzymes; References; Chapter 3: Anticancer Drugs That Modulate Hormone Action; 1. Introduction; 2. Estrogens and Their Involvement in Carcinogenesis; 3. Antiestrogens as Antitumor Drugs.8 a3.1. Nonsteroidal Antiestrogens (Selective Estrogen Receptor Modulators)3.2. Steroidal Antiestrogens; 4. Aromatase Inhibitors; 4.1. Aromatase Mechanism of Action; 4.2. Steroidal Aromatase Inhibitors (Type I Inhibitors); 4.3. C-19 Modified Substrate Analogs; 4.4. 4-Hydroxyandrostenedione Derivatives; 4.5. Steroids with Additional Unsaturations at the A and B Rings; 4.6. Structure-Activity Relationships in Steroidal Aromatase Inhibitors; 4.7. Nonsteroidal Aromatase Inhibitors (Type II); 5. Steroid Sulfatase Inhibitors; 6. Androgen-Related Antitumor Agents; 6.1. Antiandrogens. 0aCancerxChemotherapy. 0aDrugsxDesign. 0aPharmaceutical chemistry. 7aCancerxChemotherapy.2fast0(OCoLC)fst00845327 7aDrugsxDesign.2fast0(OCoLC)fst00898790 7aPharmaceutical chemistry.2fast0(OCoLC)fst01060115 2aNeoplasmsxtherapy.0(DNLM)D009369Q000628 2aDrug Design.0(DNLM)D015195 2aChemistry, Pharmaceutical.0(DNLM)D002626 4aElectronic books.1 aMen�endez, J. Carlosq(Jos�e Carlos)08iPrint version:aAvendano, Carmen.tMedicinal Chemistry of Anticancer Drugs.dBurlington : Elsevier Science, �2015z9780444626493403ScienceDirectuhttp://www.sciencedirect.com/science/book/9780444626493